FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023733075> ?p ?o ?g. }

• W2023733075 endingPage "200" @default.
• W2023733075 startingPage "200" @default.
• W2023733075 abstract "To investigate the efficacy and safety of ABT-874, an interleukin 12/23 monoclonal antibody, in psoriasis.Phase 2, 12-week, multicenter, randomized, double-blind, placebo-controlled trial.Outpatient dermatology clinics. Patients One hundred eighty patients with clinically stable moderate to severe chronic plaque psoriasis. Interventions Patients were randomized in groups of 30 to receive 1 of 6 treatments with ABT-874 provided as a subcutaneous injection: one 200-mg dose at week 0; 100 mg every other week for 12 weeks; 200 mg weekly for 4 weeks; 200 mg every other week for 12 weeks; 200 mg weekly for 12 weeks; or placebo. Main Outcome Measure At least a 75% reduction in the Psoriasis Area and Severity Index.The percentage of patients achieving a 75% reduction in the Psoriasis Area and Severity Index at week 12 was statistically significantly greater in all of the ABT-874 treatment groups than in the placebo group (200 mg once, 63% [19 of 30]; 100 mg every other week for 12 weeks, 93% [28 of 30]; 200 mg weekly for 4 weeks, 90% [27 of 30]; 200 mg every other week for 12 weeks, 93% [28 of 30]; 200 mg weekly for 12 weeks, 90% [27 of 30]; placebo, 3% [1 of 30]; P < .001). Treatment with ABT-874 was well tolerated. The most common adverse event was injection-site reaction, and the most common infectious adverse events were nasopharyngitis and upper respiratory tract infection. There were no serious infectious adverse events.ABT-874, an interleukin 12/23 monoclonal antibody, was highly effective and well tolerated in the treatment of psoriasis. Longer-term studies are required to confirm these findings." @default.
• W2023733075 created "2016-06-24" @default.
• W2023733075 creator A5002050606 @default.
• W2023733075 creator A5009369964 @default.
• W2023733075 creator A5014063407 @default.
• W2023733075 creator A5059337854 @default.
• W2023733075 creator A5061849637 @default.
• W2023733075 creator A5075798284 @default.
• W2023733075 date "2008-02-01" @default.
• W2023733075 modified "2023-10-18" @default.
• W2023733075 title "Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis" @default.
• W2023733075 cites W1556049736 @default.
• W2023733075 cites W1898779455 @default.
• W2023733075 cites W1965942174 @default.
• W2023733075 cites W1986455689 @default.
• W2023733075 cites W1987628377 @default.
• W2023733075 cites W1994127723 @default.
• W2023733075 cites W2008716526 @default.
• W2023733075 cites W2013488106 @default.
• W2023733075 cites W2019320114 @default.
• W2023733075 cites W2036635436 @default.
• W2023733075 cites W2055018575 @default.
• W2023733075 cites W2062110203 @default.
• W2023733075 cites W2065284615 @default.
• W2023733075 cites W2065523538 @default.
• W2023733075 cites W2067327580 @default.
• W2023733075 cites W2071343804 @default.
• W2023733075 cites W2082278363 @default.
• W2023733075 cites W2107235439 @default.
• W2023733075 cites W2107730744 @default.
• W2023733075 cites W2110888991 @default.
• W2023733075 cites W2129137973 @default.
• W2023733075 cites W2130925114 @default.
• W2023733075 cites W2133657961 @default.
• W2023733075 cites W2134206785 @default.
• W2023733075 cites W2164533070 @default.
• W2023733075 cites W2164687941 @default.
• W2023733075 cites W2172257129 @default.
• W2023733075 cites W2955331105 @default.
• W2023733075 cites W81829693 @default.
• W2023733075 doi "https://doi.org/10.1001/archdermatol.2007.63" @default.
• W2023733075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18283176" @default.
• W2023733075 hasPublicationYear "2008" @default.
• W2023733075 type Work @default.
• W2023733075 sameAs 2023733075 @default.
• W2023733075 citedByCount "203" @default.
• W2023733075 countsByYear W20237330752012 @default.
• W2023733075 countsByYear W20237330752013 @default.
• W2023733075 countsByYear W20237330752014 @default.
• W2023733075 countsByYear W20237330752015 @default.
• W2023733075 countsByYear W20237330752016 @default.
• W2023733075 countsByYear W20237330752017 @default.
• W2023733075 countsByYear W20237330752018 @default.
• W2023733075 countsByYear W20237330752019 @default.
• W2023733075 countsByYear W20237330752020 @default.
• W2023733075 countsByYear W20237330752021 @default.
• W2023733075 countsByYear W20237330752022 @default.
• W2023733075 countsByYear W20237330752023 @default.
• W2023733075 crossrefType "journal-article" @default.
• W2023733075 hasAuthorship W2023733075A5002050606 @default.
• W2023733075 hasAuthorship W2023733075A5009369964 @default.
• W2023733075 hasAuthorship W2023733075A5014063407 @default.
• W2023733075 hasAuthorship W2023733075A5059337854 @default.
• W2023733075 hasAuthorship W2023733075A5061849637 @default.
• W2023733075 hasAuthorship W2023733075A5075798284 @default.
• W2023733075 hasBestOaLocation W20237330751 @default.
• W2023733075 hasConcept C126322002 @default.
• W2023733075 hasConcept C141071460 @default.
• W2023733075 hasConcept C142724271 @default.
• W2023733075 hasConcept C16005928 @default.
• W2023733075 hasConcept C168563851 @default.
• W2023733075 hasConcept C197934379 @default.
• W2023733075 hasConcept C204787440 @default.
• W2023733075 hasConcept C27081682 @default.
• W2023733075 hasConcept C2776173921 @default.
• W2023733075 hasConcept C2777011040 @default.
• W2023733075 hasConcept C2780564577 @default.
• W2023733075 hasConcept C2780805593 @default.
• W2023733075 hasConcept C71924100 @default.
• W2023733075 hasConcept C90924648 @default.
• W2023733075 hasConceptScore W2023733075C126322002 @default.
• W2023733075 hasConceptScore W2023733075C141071460 @default.
• W2023733075 hasConceptScore W2023733075C142724271 @default.
• W2023733075 hasConceptScore W2023733075C16005928 @default.
• W2023733075 hasConceptScore W2023733075C168563851 @default.
• W2023733075 hasConceptScore W2023733075C197934379 @default.
• W2023733075 hasConceptScore W2023733075C204787440 @default.
• W2023733075 hasConceptScore W2023733075C27081682 @default.
• W2023733075 hasConceptScore W2023733075C2776173921 @default.
• W2023733075 hasConceptScore W2023733075C2777011040 @default.
• W2023733075 hasConceptScore W2023733075C2780564577 @default.
• W2023733075 hasConceptScore W2023733075C2780805593 @default.
• W2023733075 hasConceptScore W2023733075C71924100 @default.
• W2023733075 hasConceptScore W2023733075C90924648 @default.
• W2023733075 hasIssue "2" @default.
• W2023733075 hasLocation W20237330751 @default.
• W2023733075 hasLocation W20237330752 @default.
• W2023733075 hasOpenAccess W2023733075 @default.

• next